Esophageal cancer (EC) has two primary subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). These subtypes differ notably in geographical distribution, risk factors, and clinical characteristics. Despite considerable efforts, EC remains challenging to diagnose and treat due to its frequently late presentation and resistance to conventional therapies.
A comprehensive review (DOI: 10.20892/j.issn.2095-3941.2023.0177), conducted by researchers at Zhengzhou University, Henan Cancer Hospital, and the Marshall Medical Research Center, marks a significant advancement in oncology. Published in the October 2023 issue of Cancer Biology & Medicine, the review highlights important findings regarding microbiome changes in EC and their implications for disease pathogenesis and prognosis. It identifies critical shifts in the microbiome associated with EC and explores how these changes might affect patient outcomes.
The researchers found that specific bacterial changes are linked to different stages of EC. For example, lactic acid-producing bacteria were more common in EAC, suggesting these microbes might support tumor survival by converting glucose into lactate, providing energy for malignant cells. They also noted reduced microbial diversity in ESCC compared to non-tumor tissues. This decrease in diversity was associated with increased levels of Fusobacterium and decreased levels of Streptococcus, indicating that specific microbial profiles may play a role in cancer progression. The study further explored how microbial dysbiosis might affect treatment outcomes. Distinct microbial compositions were associated with varied responses to radiotherapy and chemotherapy, emphasizing the potential of the esophageal microbiome to influence treatment efficacy.
“Understanding the role of the esophageal microbiome in the development and progression of EC could lead to earlier detection and more personalized treatment approaches,” stated Dr. Hongle Li, one of the study’s authors. “Our findings suggest that microbial dysbiosis may not only contribute to the pathogenesis of EC but also affect treatment outcomes.”
The research has critical implications for early detection and improved treatment strategies for EC. Identifying microbial markers associated with disease progression could pave the way for targeted therapies that disrupt cancer-promoting bacteria. Moreover, certain microbial profiles could serve as prognostic indicators, aiding in treatment planning and patient monitoring.
###
References
DOI
10.20892/j.issn.2095-3941.2023.0177
Original Source URL
https://doi.org/10.20892/j.issn.2095-3941.2023.0177
Funding information
This work was supported by grants from the Health Commission of Henan Province (Grant No. SBGJ20211008) and the Henan Provincial Department of Science and Technology (Grant No. 222300420574).
About Cancer Biology & Medicine (CBM)
Cancer Biology & Medicine (CBM) is a peer-reviewed open-access journal sponsored by China Anti-cancer Association (CACA) and Tianjin Medical University Cancer Institute & Hospital. The journal monthly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The journal is indexed in SCOPUS, MEDLINE and SCI (IF 5.5, 5 year IF 6.1), with all full texts freely visible to clinicians and researchers all over the world (http://www.ncbi.nlm.nih.gov/pmc/journals/2000/).
